StockTipsArenaBeta

BUY Aurobindo Pharma — Kshitija Salvi, Globe Capital Market

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byKshitija Salvi, Globe Capital MarketHorizon: NA (inferred Swing (≤2wk))27 Jul 2026via CNBC Awaaz.

Entry₹1,565.6Inferred
Target₹1,675
Total upside +6.99% (call closed)
Stop loss₹1,527-2.47% risk
At expiry₹1,6587 Aug 2026, 3:30 pm
Expired+5.90%auction close
Follow Kshitija Salvi for new calls(14% target hit, 29 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 1 active Swing call on AUROPHARMASee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 7 Aug 2026
12 supporting4 neutral3 opposing
Supports the BUY call (12)

Aurobindo Pharma rises 3% after Q1 beat; HDFC Securities retains 'Add', Axis Securities cuts to 'Hold'

NewsGoogle News·7 Aug · today

(opens in new tab)

Hold Aurobindo Pharma; target of Rs 1600: Prabhudas Lilladher

NewsGoogle News·7 Aug · today

(opens in new tab)

3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·7 Aug · today

Aurobindo Pharma Shares Tumble 2% Despite Q1 Profit Jump, Double Digit Revenue Guidance For FY27

NewsNdtv-Profit·6 Aug · yesterday

(opens in new tab)

Aurobindo Pharma's Q1 Margin Story Improves; Macquarie Says Growth Picture Is Still Uneven

NewsNdtv-Profit·6 Aug · yesterday

(opens in new tab)
Neutral / worth noting (4)

Aurobindo Pharma has announced its unaudited financial results for the first quarter ended June 30, 2026. The company has provided a press release detailing these results.

NSE · Press Release·5 Aug · yesterday

(opens in new tab)

Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·5 Aug · yesterday

(opens in new tab)

Aurobindo Pharma signs licensing pact with Merck to supply generic HIV drug in 129 countries

NewsCnbc-Tv18·24 Jul · 2w ago

(opens in new tab)

Aurobindo Pharma arm Apitoria to acquire 80% stake in A1 Biochem Group for $17 million

NewsCnbc-Tv18·23 Jul · 2w ago

(opens in new tab)
Weighs against the BUY call (3)

1 advisor has an active short-term SELL call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·6 Aug · yesterday

US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline

NewsHbl·22 Jul · 2w ago

(opens in new tab)

Pharma stocks decline; Aurobindo Pharma down over 4%

NewsHbl·22 Jul · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Kshitija Salvi, Globe Capital Market

Every call and its outcome